Proteomics for hepatocellular carcinoma marker discovery
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Gastroenterology
(Impact Factor: 16.72).
12/2004; 127(5 Suppl 1):S120-5. DOI: 10.1053/j.gastro.2004.09.025
Refinements of serological markers and screening of patients at high risk for developing hepatocellular carcinoma (HCC) may lead to better HCC detection, earlier intervention, and successful treatment, improving long-term outcomes. Proteomics promises the discovery of biomarkers for early HCC detection and diagnosis. Proteomic-based profiling uniquely allows delineation of global changes in expression patterns resulting from transcriptional and posttranscriptional control, posttranslational modifications, and shifts in proteins between cellular compartments. Approaches to that effect include direct serum protein profiling and comparative analysis of protein expression in normal, precancerous, and early-stage tumor tissues. Identification of panels of tumor antigens that elicit a humoral response also may contribute to the discovery of new markers for HCC screening and diagnosis. Today, 2-dimensional polyacrylamide gel electrophoresis, multidimensional liquid chromatography, mass spectrometry, and protein microarrays are among the proteomic tools available for biomarker and drug target discovery. We review these technologies and their application to the study of HCC. Our objective is to provide a framework for appreciating the promise, while at the same time understanding the challenges behind translating proteomics discovery into novel diagnostic tests.
Available from: Xue Bai
- "The majority of the malignant tumors were in the advanced stage when they were diagnosed, with extensive metastases. Therefore, new suitable tumor markers were especially important for the early diagnosis and treatment of malignant tumors (Chignard and Beretta, 2004). Colonoscopy is a reliable means for the screening and diagnosis of CRC. "
[Show abstract] [Hide abstract]
ABSTRACT: Laser capture microdissection and two-dimensional difference gel electrophoresis were used to establish the proteomic profiles for tumor and matched adjacent tissues from 12 patients. Differential protein spots were identified by mass spectrometric analysis. The cDNA of the differential protein was transfected into colorectal cancer cells, and the biological behavior of these cells was observed. The proteomic profile in colorectal cancer tissues was significantly different from that in normal adjacent tissues. There was a 1.5-fold difference and 60 differential protein spots between cancer and adjacent tissues. Ten differential protein spots were analyzed. Among them, two protein spots were down-regulated and eight protein spots were up-regulated in the primary tumor tissues. After identification by mass spectrometry, the two down-regulated proteins were carbonic anhydrase II and protein disulfide isomerase, and these eight up-regulated proteins included APC-stimulated guanine nucleotide exchange factor, phosphoglycerate kinase 1, fumarate hydratase, aldolase A, activator protein 2B, glutathione S-transferase A3, Arginase and zinc finger protein 64 homolog. After been transfected with carbonic anhydrase II, the invasive ability, mobility and drug resistance of colon cancer lovo cells were significantly reduced. The proteomic profile was significantly different between colorectal cancer tissues and normal adjacent tissues. The down-regulation of carbonic anhydrase II and protein disulfide isomerase and up-regulation of APC-stimulated guanine nucleotide exchange facto, aldolase A, glutathione S-transferase A3 and arginase were correlated with the onset of colorectal cancer.
AFRICAN JOURNAL OF BIOTECHNOLOGY 10/2010; 9(41). · 0.57 Impact Factor
Available from: Suzan M Semaan
- "Currently SELDI have been used for evaluating serum fi nding it useful for the discovery and identifi cation of potential biomarkers (Li et al. 2002; Petricoin et al. 2002a; Qu et al. 2002; Petricoin et al. 2002b; Petricoin et al. 2002c; Issaq et al. 2002; Miguet et al. 2006). Although limitations during large profi ling experiments, where some observations noted that spectra can vary based on analytical factors (such as the time of processing, issues in the reproducibility of SELDI (Petricoin et al. 2002a; Deng et al. 2003; Diamandis, 2003), and usually unidentifi ed individual proteins (Chignard and Beretta, 2004)), there are advantages that include prior to analysis removal of components (salts or detergents) that commonly cause problems with other analytical tools, thus leaving only those proteins that are actively interacting with the spot surfaces to be analyzed in the ProteinChip Reader (Romer et al. 2002). "
[Show abstract] [Hide abstract]
ABSTRACT: Biomarkers are biomolecules that serve as indicators of biological and pathological processes, or physiological and pharmacological responses to a drug treatment. Because of the high abundance of albumin and heterogeneity of plasma lipoproteins and glycoproteins, biomarkers are difficult to identify in human serum. Due to the clinical significance the identification of disease biomarkers in serum holds great promise for personalized medicine, especially for disease diagnosis and prognosis. This review summarizes some common and emerging proteomics techniques utilized in the separation of serum samples and identification of disease signatures. The practical application of each protein separation or identification technique is analyzed using specific examples. Biomarkers of cancers of prostate, breast, ovary, and lung in human serum have been reviewed, as well as those of heart disease, arthritis, asthma, and cystic fibrosis. Despite the advancement of technology few biomarkers have been approved by the Food and Drug Administration for disease diagnosis and prognosis due to the complexity of structure and function of protein biomarkers and lack of high sensitivity, specificity, and reproducibility for those putative biomarkers. The combination of different types of technologies and statistical analysis may provide more effective methods to identify and validate new disease biomarkers in blood.
Biomarker insights 02/2007; 2:21-43.
Available from: Cristian Baicus
[Show abstract] [Hide abstract]
ABSTRACT: A recent theory stipulates that during the course of HIV infection, there is a shift in immune response from T-helper 1 to T-helper 2 responses, characterised by elevated secretions of relevant cytokines. Cytokine profiles of 15 asymptomatic (treatment naïve) and 26 symptomatic (undergoing treatment) HIV-1 patients was determined to investigate the validity of this theory. HIV-1 RNA was quantified using the COBAS TaqMan HIV-1 test, CD4 T-cell counts with the FACSCalibur flow cytometer and IL-1, IL-4, IL-6, IL-10 and IFN-gamma cytokine levels by ELISA method. The asymptomatic group had significantly higher RNA levels (p-value; 0.000006) and lower CD4 T-cell counts than the symptomatic group indicating ongoing disease progression in the absence of antiretroviral treatment and a positive response to HIV treatment by the symptomatic group. IL-1, IL-4 and IFN-gamma were undetectable in most study subjects. IL-10 and IL-6 levels was relatively lower in the asymptomatic group (mean value; 206.352 pg/ml, 10.516 pg/ml) than the symptomatic group (mean value; 417.539, 18.387 pg/ml). Lower levels of proinflammatory cytokines (IL-1, IFN-gamma) in both study groups and elevated levels of anti-inflammatory cytokine IL-10, confirms that there is a shift in immune response as HIV infection progress to AIDS. In addition, the presence of a progressive trend of anti-inflammatory cytokine, IL-10 and proinflammatory cytokine, IL-6 in 12 symptomatic patients tested 3 months after antiretroviral therapy indicates an attempt by antiretrovirals to restore immune function.
Roumanian archives of microbiology and immunology 01/2010; 69(1):24-34.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.